EU/3/03/171
About
Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in October 2019 at the end of the 10-year period of market exclusivity.
On 17 October 2003, orphan designation (EU/3/03/171) was granted by the European Commission to PharmaMar S.A., Spain, for trabectedin for the treatment of ovarian cancer.
Ecteinascidin 743 in treatment of ovarian cancer has been authorised in the EU as Yondelis since 28 October 2009.
Key facts
Active substance |
trabectedin
|
Medicine name |
Yondelis
|
Disease / condition |
Treatment of ovarian cancer
|
Date of first decision |
17/10/2003
|
Outcome |
Expired
|
EU designation number |
EU/3/03/171
|
Sponsor's contact details
PharmaMar S.A.
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Madrid
Spain
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
E-mail: pharmamar@pharmamar.com
Polígono Industrial La Mina
Av. de los Reyes 1
28770 Colmenar Viejo
Madrid
Spain
Telephone: (34-91) 846 60 00
Telefax: (34-91) 823 45 03
E-mail: pharmamar@pharmamar.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: